Contineum Therapeutics Future Growth

Future criteria checks 0/6

Contineum Therapeutics's revenue is forecast to decline at 18.6% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	24.0%
Revenue growth rate	-18.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	19 Nov 2024

Recent future growth updates

No updates

Recent updates

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Oct 07

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 13

Earnings and Revenue Growth Forecasts

NasdaqGS:CTNM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	N/A	-68	-68	2
12/31/2025	10	N/A	-42	-42	3
12/31/2024	N/A	N/A	-31	-30	3
9/30/2024	N/A	-29	-34	-33	N/A
6/30/2024	N/A	-20	-33	-33	N/A
3/31/2024	50	0	16	17	N/A
12/31/2023	50	3	19	19	N/A
9/30/2023	50	-3	26	26	N/A
12/31/2022	N/A	-24	-20	-20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CTNM's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if CTNM's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CTNM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CTNM's revenue is expected to decline over the next 3 years (-18.6% per year).

High Growth Revenue: CTNM's revenue is forecast to decline over the next 3 years (-18.6% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CTNM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 17:40
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Contineum Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Jeff Hung	Morgan Stanley
Luke Davis	RBC Capital Markets